Vericiguat and "Worsening Heart Failure" Protocols
For patients who experience a "decompensation event" (an emergency hospital visit for heart failure), 2026 protocols now emphasize the use of Vericiguat. This is a soluble guanylate cyclase (sGC) inhibitor that directly relaxes blood vessels and improves heart function.
It is specifically indicated for patients who are already on the "Four Pillars" but continue to show signs of worsening disease. By 2026, it is used as an "add-on" therapy to prevent the "revolving door" of hospital readmissions.
2 visualizações